Efficacy and tolerability of RPL 554 in patients with allergic rhinitis
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2013
Price : $35 *
At a glance
- Drugs Ensifentrine (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions; Therapeutic Use
- 25 Oct 2013 New trial record
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 09 Sep 2013 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met.